Entera Bio Stock Discussion

$Entera Bio (ENTX.US)$
Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
Tuesday, 15th April at 8:30 am
JERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman's oral presentation a...

$Entera Bio (ENTX.US)$
Game-Changing Oral Osteoporosis Treatment Matches Injectable Efficacy in Clinical Trial

$Entera Bio (ENTX.US)$ Answer was expected by end of January from The FDA decision to move forward on The SABRE (Study to Advance Bone Mineral Density as a Regulatory Endpoint), based on a statistical meta-analysis of over 170,000 patients across 53 randomized clinical studies and 7 osteoporosis drug classes correlating total hip BMD to fracture outcomes, is undergoing review at FDA

$Opko Health (OPK.US)$ $Entera Bio (ENTX.US)$ Reuters· 1 min ago
OPKO Health and Entera Bio Enter Into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate Into the Clinic to Treat Obesity and Metabolic Disorders

$Entera Bio (ENTX.US)$ $Opko Health (OPK.US)$
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Monday, 17th March at 8:00 am
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement...

$Opko Health (OPK.US)$ $Entera Bio (ENTX.US)$ Reuters· 1 min
Entera Bio and OPKO Health Provide Update on Pk/Pd Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

$Entera Bio (ENTX.US)$
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
Entera Bio (NASDAQ: ENTX) and OPKO Health, Inc. (NASDAQ: OPK) have announced positive results from their collaborative research on an oral oxyntomodulin (OXM) peptide tablet for obesity and metabolic disorders. The study, combining OPKO's proprietary long-acting OXM analog with Entera's N-Tab™ technology, aims to ...